Mometasona Viatris (Mometasone Furoate)

Mometasone furoate binds to glucocorticoid receptors inside skin cells, forming a complex that enters the nucleus and alters gene expression. This suppresses the production of inflammatory cytokines and mediators, leading to decreased inflammation, reduced immune cell activity, and relief of symptoms such as redness, swelling, and itching.

The appropriate dose of Mometasona Viatris is determined by the prescribing clinician based on the specific condition, severity, patient age, and treatment area. The prescriber will provide instructions on the amount to apply, frequency of application, and duration of therapy tailored to the individual’s needs.

Safety data for topical mometasone furoate during pregnancy and lactation are limited. Healthcare providers generally weigh the potential benefits against possible risks before prescribing. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss the use of Mometasona Viatris with their physician to determine if it is appropriate.

To order Mometasona Viatris, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team will provide pricing, availability, shipping details (including any cold‑chain requirements), and assist with import documentation.

Mometasona Viatris contains mometasone furoate, a high‑potency corticosteroid with strong anti‑inflammatory activity, often considered more potent than hydrocortisone or betamethasone but less potent than clobetasol. Its efficacy in reducing skin inflammation is comparable to other mid‑ to high‑potency steroids, while its safety profile is similar when used as directed.

Store Mometasona Viatris at room temperature, below 25 °C, in its original packaging. Keep the container tightly closed, protect it from moisture, heat, and direct sunlight. Do not freeze the product. Ensure that the packaging is intact before use and discard any product that appears discolored or contaminated.

Mometasona Viatris is applied topically to clean, dry skin. The prescriber will advise the amount—usually a thin layer—covering the affected area. Gently rub the medication until it is evenly distributed. Wash hands before and after application unless the hands are the treatment site. Avoid contact with eyes, mouth, or open wounds unless instructed.

Serious risks, though uncommon, include skin atrophy, secondary infections (bacterial, fungal, or viral), adrenal suppression with extensive use, and allergic reactions such as contact dermatitis. Patients should report severe skin thinning, unusual bruising, persistent fever, or signs of systemic corticosteroid effects to their healthcare provider promptly.

Mometasona Viatris should be avoided in individuals with known hypersensitivity to mometasone furoate or any formulation components. It is also contraindicated on infected, ulcerated, or open wounds, and should not be used on large body surface areas for prolonged periods without medical supervision. Children under the age specified by the prescriber may require alternative therapies.